This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Yellow fever vaccine-associated viscerotropic disease | |
|---|---|
| Name | Yellow fever vaccine-associated viscerotropic disease |
| Synonyms | YEL-AVD |
| Field | Infectious disease, Travel medicine |
| Symptoms | Fever, jaundice, hypotension, multiorgan failure |
| Complications | Hepatic failure, renal failure, coagulopathy |
| Onset | Days after vaccination |
| Duration | Acute |
| Causes | Yellow fever 17D vaccine strain (rare pathogenic replication) |
| Diagnosis | Clinical criteria, laboratory evidence, histopathology |
| Treatment | Supportive care, intensive care |
| Prognosis | Variable; high case-fatality in severe cases |
Yellow fever vaccine-associated viscerotropic disease is a rare, severe adverse event occurring after administration of the live-attenuated yellow fever 17D vaccine, characterized by disseminated viral replication with involvement of multiple organs. It presents as an acute, fulminant syndrome resembling wild-type yellow fever with hepatic, renal, pulmonary, and hematologic failure, and has been the subject of investigation by global public health and vaccine safety authorities. High-profile vaccine safety reviews and epidemiologic surveillance programs inform current clinical guidance and travel immunization policies.
The condition was recognized following clusters and sporadic cases reported in association with the 17D vaccine strain and has been examined by bodies such as the World Health Organization, the Centers for Disease Control and Prevention, the European Medicines Agency, and national public health institutes in Brazil, United States, France, and United Kingdom. Historical vaccine development efforts involving Max Theiler and institutions like the Rockefeller Foundation contextualize the evolution of yellow fever immunization and its rare severe adverse events. Investigations have involved collaborations with academic centers including Johns Hopkins University, Oxford University, and University of São Paulo.
Surveillance data from organizations such as the Pan American Health Organization and the European Centre for Disease Prevention and Control estimate incidence of viscerotropic disease at approximately 0.3–0.4 cases per 100,000 vaccine doses in general adult populations, with higher rates identified in specific cohorts during post-marketing studies. Case series reported by national agencies in Australia, Canada, Germany, and Argentina contributed to risk estimates that influenced policy changes in 2001–2010 era vaccine recommendations. Outbreak investigations and vaccine pharmacovigilance databases maintained by the Vaccine Adverse Event Reporting System and the Global Advisory Committee on Vaccine Safety provide ongoing incidence monitoring.
Pathogenesis involves uncontrolled replication of the vaccine virus leading to viscerotropic infection, with host factors implicated by case-control and molecular studies from centers like Centers for Disease Control and Prevention and Institut Pasteur. Identified risk factors include advanced chronological age, thymic disease or thymectomy status as documented in patient registries and case reports, and certain immunologic impairments evaluated in cohorts at Mayo Clinic and Karolinska Institutet. Genetic susceptibility hypotheses have prompted investigations involving genomic centers such as Broad Institute and Wellcome Sanger Institute, while viral genetic stability work has involved laboratories at Yale University and University of Geneva.
Clinically, patients typically develop systemic features within days to weeks of vaccination, presenting with high fever, profound fatigue, jaundice, hypotension, and laboratory abnormalities including elevated aminotransferases, creatinine, and coagulopathy; case descriptions have been published in journals from New England Journal of Medicine, The Lancet, and Journal of Infectious Diseases. Diagnostic evaluation integrates virologic assays performed by reference laboratories like Centers for Disease Control and Prevention Arbovirus Diagnostic Laboratory and sequencing centers at Sanger Institute, plus histopathologic findings described in reports from Mayo Clinic and Mount Sinai Hospital. Differential diagnosis often involves exclusion of wild-type yellow fever exposure, dengue and other flaviviruses documented by surveillance in regions such as West Africa, Central Africa, and Brazil.
No specific antiviral therapy has proven efficacy; management follows intensive supportive care principles established in critical care guidelines from institutions such as Society of Critical Care Medicine and European Society of Intensive Care Medicine. Reported interventions in case reports from Massachusetts General Hospital and Charité – Universitätsmedizin Berlin include hemodynamic support, renal replacement therapy, correction of coagulopathy, and management of secondary infections using antimicrobial stewardship frameworks endorsed by Infectious Diseases Society of America. Experimental approaches and convalescent plasma have been discussed in research settings at National Institutes of Health and university clinical trials units.
Outcomes range from full recovery to fatal multisystem organ failure; published case series aggregated by the World Health Organization and the Centers for Disease Control and Prevention report a high case-fatality ratio among confirmed viscerotropic cases, particularly in older adults and those with comorbid thymic disease. Long-term sequelae in survivors, documented in cohort follow-up studies at University College London and University of São Paulo, may include persistent hepatic dysfunction and prolonged convalescence. Mortality trends and outcome predictors continue to be analyzed by public health agencies including Public Health England and the European Medicines Agency pharmacovigilance networks.
Preventive strategies emphasize risk stratification prior to immunization following guidelines from World Health Organization position papers, Centers for Disease Control and Prevention yellow fever vaccine recommendations, and national immunization technical advisory groups such as Advisory Committee on Immunization Practices. Contraindications and precautions reflect findings from safety reviews by the European Medicines Agency and advisory panels convened by Pan American Health Organization, including screening for thymic disorders and careful consideration of vaccination in elderly travelers to endemic areas like Angola, Ghana, and Brazil. Enhanced post-vaccination surveillance, manufacturer pharmacovigilance by companies with historic vaccine portfolios, and research collaborations involving Bill & Melinda Gates Foundation and academic consortia aim to refine risk communication, vaccine strain monitoring, and candidate non-replicating alternatives under development at institutions such as NIH Vaccine Research Center.
Category:Vaccine adverse events